Sinovac BiotechSVA
13F holders, Q1 2025 (March 31)3holders −1
0new positions
1sold out
$110.75avg. 13F price*
At the end of Q1 2025, 3 institutions reported holding Sinovac Biotech Ltd. (SVA) in their 13F filings, down 1 from Q4 2024. 0 opened new positions and 1 sold out. The largest holders were Orbimed Advisors LLC ($334.0M), Neumann Advisory Hong Kong Ltd ($2.0M) and Financial Gravity Asset Management, Inc. ($0).
- Company
- Sinovac Biotech Ltd.
- CUSIP
- P8696W104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $0 |
All 13F filers, Q4 2024 → Q1 2025: 14,167 shares sold, net −14,167 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Orbimed Advisors LLC | 8.02% | No change | 2,718,735 | $334.0M |
| Neumann Advisory Hong Kong Ltd | 0.88% | No change | 315,586 | $2.0M |
| Financial Gravity Asset Management, Inc. | 0.00% | — | 23 | $0 |
"% of holder's portfolio" is SVA's weight in each manager's 13F, not the share of Sinovac Biotech Ltd. the manager owns.